How does trastuzumab Herceptin work?
Herceptin works by attaching itself to the HER2 receptors on the surface of breast cancer cells and blocking them from receiving growth signals. By blocking the signals, Herceptin can slow or stop the growth of the breast cancer. Herceptin is an example of an immune targeted therapy.
How does trastuzumab work in breast cancer?
Trastuzumab works by attaching itself to the HER2 proteins so that the cancer cells are no longer stimulated to grow. It also helps the body’s immune system destroy breast cancer cells.
Is trastuzumab fully humanized?
Trastuzumab (Herceptin, Genentech, Inc., South San Francisco, California) is a highly purified recombinant DNA-derived humanized monoclonal immunoglobulin G1 kappa antibody that binds with high affinity and specificity to the extracellular domain of the HER2 receptor.
Why does resistance to the trastuzumab occur?
Trastuzumab-induced growth inhibition in HER2-overexpressing cells can be compensated for by increased IGF-IR signaling, resulting in resistance to trastuzumab.
How effective is trastuzumab?
A study of more than 4000 patients, published in 2014, showed that adding trastuzumab to chemotherapy led to a 37% relative improvement in overall survival, increasing 10-year survival from 75.2% to 84%. The 10-year disease-free survival rate increased from 62.2% to 73.7%. All patient subgroups benefited.
Is trastuzumab chemotherapy or immunotherapy?
These are active specific immunotherapy with Theratope and passive immunotherapy targeting the HER-2 receptor with trastuzumab (Herceptin). Trastuzumab has a proven efficacy as monotherapy as well as in combination with chemotherapeutic agents in HER-2-overexpressing metastatic breast cancer.
Does trastuzumab cause hair loss?
Answer: No, hair loss is not a common side effect of trastuzumab. If you are receiving trastuzumab in combination with chemotherapy, you may experience hair loss due to the chemotherapy.
What is the role of trastuzumab?
Trastuzumab is a monoclonal antibody that is used in the treatment of breast cancer. Trastuzumab targets the human epidermal growth factor receptor 2 (HER2) receptor on breast cancer cells that express this tyrosine kinase receptor. These cancers are referred to as HER2-positive breast cancer.
How is 89zr-trastuzumab used in PET imaging?
We performed a feasibility study to determine the optimal dosage and time of administration of the monoclonal antibody zirconium-89 ( (89)Zr)-trastuzumab to enable positron emission tomography (PET) imaging of human epidermal growth factor receptor 2 (HER2)-positive lesions.
What is the decay half life of 89Zr?
Positron emission tomography (PET) imaging with radiolabeled monoclonal antibodies has always been a dynamic area in molecular imaging. With decay half-life (3.3 d) well matched to the circulation half-lives of antibodies (usually on the order of days), 89Zr has been extensively studied over the last decade.
Are there any PET tracers based on 89Zr?
With well-developed radiochemistry, commercial availability of chelating agents for 89Zr labeling, increasingly widely available isotope supply, as well as successful proof-of-principle in pilot human studies, it is expected that PET imaging with 89Zr-based tracers will be a constantly evolving and highly vibrant field in the near future.
Which is the stable isotope of zirconium 89?
89Zr, which decays by positron emission (23%) and electron capture (77%) to the stable isotope 89Y, has attractive characteristics for immunoPET applications. The physical decay half-life of 89Zr is 3.3 days, which is compatible with the time needed to achieve optimal tumor-to-background ratios for intact mAbs (typically a few days).